As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

RVPH RECOVER Vocal Biomarker Data On September 4, 2024, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) held a key ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

New safety data shows an absence of post-injection syndrome, a rare and serious side effect of long-acting olanzapine.

Newron today announces its financial and operational results for the half year ended June 30, 2024, and provides an update on ...

There is no single test to diagnose schizophrenia. Healthcare professionals may use a variety of tests to rule out other ...

Neurocrine Biosciences Inc.’s top-line phase II data, though billed as promising, wasn’t enough to please observers on Wall Street, who stacked the data in schizophrenia with NBI-1117568 (NBI-'568) ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new positive efficacy, safety and ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...

It appears shareholders were spooked by the size of the reduction in PANSS – a 7.5 improvement on placebo and an 18.2-point fall from baseline – compared to similarly-acting rival therapies in ...